Skip to main content

Table 5 3-Year PFS and OS Rates

From: A phase II study of concurrent chemo-radiotherapy with weekly nedaplatin in advanced squamous cell carcinoma of the uterine cervix

 

No. of patients

The 3-year PFS (%)

P-value

The 3-year OS (%)

P-value

All patients

24

87.5

-

91.5

-

Stage

     

  IIa2

3

3/3

 

3/3

 

  IIb

18

88.9

 

88.9

 

  IIIb

3

2/3

0.360

3/3

0.710